Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 4/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28151437 | 0.79 | LMNA (0.41) | TRPV4LMNAFABP4EDNRATP53 | |
| SCHEMBL14165763 | 0.79 | LMNA (0.35) | TRPV4LMNAEDNRATP53MAPT | |
| SCHEMBL28301304 | 0.78 | MAPT (0.37) | TRPV4LMNAFABP4EDNRATP53 | |
| SCHEMBL9571061 | 0.76 | LMNA (0.34) | LMNAFABP4 | |
| SCHEMBL8563046 | 0.73 | SMN1; SMN2 (0.48) | LMNAEDNRATP53 | |
| SCHEMBL11484963 | 0.72 | LMNA (0.36) | TRPV4LMNAEDNRA | |
| SCHEMBL388034 | 0.71 | MAPT (0.55) | LMNAEDNRATP53MAPT | |
| SCHEMBL384644 | 0.70 | TRPV4 (0.38) | TRPV4LMNAEDNRAMAPT | |
| SCHEMBL5559189 | 0.70 | LMNA (0.33) | TRPV4LMNA | |
| SCHEMBL1035114 | 0.68 | LMNA (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| WO-2021105335-A1 | PIPERIDINE-2, 6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2021-06-03 | — | — | WO | disclosed |
| EP-1330458-B1 | N-( 1,2,4 TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2009-06-03 | — | — | EP | disclosed |
| CN-1221552-C | N- ((1,2, 4) triazoloazinyl) thiophene sulfonamide compounds as herbicides | DOW AGROSCIENCES LLC (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1471533-A | N-([1,2,4] triazoloazinyl) thiophene sulfonamide compounds as herbicides | �ݶ�ũ������˾ | 2004-01-28 | — | — | CN | disclosed |
| US-6645918-B1 | N-(Triazolo(1,5-a)pyrimidinyl)thiophenesulfonamide compounds; postemergence herbicides; agriculture | DOW AGROSCIENCES LLC | 2003-11-11 | — | — | US | disclosed |
| US-20030199393-A1 | N- ([1,2,4,] TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | ARNDT KIM ERIC (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1330458-A1 | N-( 1,2,4]TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AS HERBICIDES | Dow Agrosciences LLC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6518222-B2 | Prepared from 2-amino(1,2,4)triazolo(1,5-c)pyrimidine, 2-amino(1,2,4)triazolo(1,5-a)pyrimidine, and 2-amino(1,2,4)triazolo(1,5-a)pyridine compounds and thiophenesulfonyl chloride compounds | DOW AGROSCIENCES LLC | 2003-02-11 | — | — | US | disclosed |
| US-20020094935-A1 | N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides | DOW AGROSCIENCES LLC | 2002-07-18 | — | — | US | disclosed |
| WO-2002038572-A1 | N-([1,2,4]TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094935-A1 | N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides | PNPO, NAT1, DDT | TRPV4 3109/4885LMNA 4863/4885PTGS2 2933/4885 |
| US-20030199393-A1 | N- ([1,2,4,] TRIAZOLOAZINYL) THIOPHENESULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | NAT1, TST, TASP1 | TRPV4 1818/4885LMNA 4782/4885PTGS2 3118/4885 |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | TRPV4 3339/4885LMNA 1716/4885PTGS2 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.